As demand for highly potent therapies continues to grow, pharmaceutical companies are facing increasing challenges in safely developing and manufacturing HPAPIs across every stage of the product lifecycle.
From containment requirements and regulatory complexity to scalability and technology transfer, HPAPI manufacturing requires highly specialized infrastructure, advanced safety systems and integrated development capabilities.
Beyond Containment
Highly Potent Active Pharmaceutical Ingredients (HPAPIs) are transforming the treatment landscape across oncology, immunology and rare diseases. Their high pharmacological activity enables targeted therapeutic effects at extremely low doses, but also introduces complex operational and safety requirements throughout development and manufacturing.
Handling compounds with occupational exposure limits as low as ≤0.1 μg/m³ requires advanced containment strategies, specialized facilities and strict operational controls capable of ensuring product integrity, operator protection and regulatory compliance.
At the same time, pharmaceutical companies must manage one of the industry’s most critical challenges: scaling up HPAPI processes from laboratory development to clinical and commercial manufacturing while maintaining consistency, quality and containment performance.
AGC Pharma Chemicals: End-to-End HPAPI Expertise
At AGC Pharma Chemicals, we support the entire HPAPI lifecycle through an integrated network of specialized facilities designed to combine scalability, flexibility and OEB5 containment capabilities.
Discover how AGC Pharma Chemicals combines advanced containment systems, scalable manufacturing infrastructure and integrated quality management to support next-generation HPAPI manufacturing.
